[
    [
        {
            "time": "",
            "original_text": "药明康德2018年净利润同比增长84.22%",
            "features": {
                "keywords": [
                    "药明康德",
                    "净利润",
                    "同比增长",
                    "84.22%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德2018年净利润同比增长84.22%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "科创板开门迎客，医药创新驱动力换挡在即｜【光大医药·周报】",
            "features": {
                "keywords": [
                    "科创板",
                    "医药创新",
                    "驱动力",
                    "换挡"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "科创板开门迎客，医药创新驱动力换挡在即｜【光大医药·周报】",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药明康德上市首份年报出炉 净利润同比增长逾八成",
            "features": {
                "keywords": [
                    "药明康德",
                    "年报",
                    "净利润",
                    "同比增长",
                    "八成"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德上市首份年报出炉 净利润同比增长逾八成",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【东吴医药】药明康德2019年年报点评：经调整Non-IFRS归母净利润增长38.2%，超市场预期，主业业绩增长表现强劲",
            "features": {
                "keywords": [
                    "东吴医药",
                    "药明康德",
                    "Non-IFRS",
                    "归母净利润",
                    "增长",
                    "38.2%",
                    "市场预期",
                    "主业业绩",
                    "增长强劲"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】药明康德2019年年报点评：经调整Non-IFRS归母净利润增长38.2%，超市场预期，主业业绩增长表现强劲",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]